Erratum: Structural and conformational determinants of macrocycle cell permeability (Nature Chemical Biology (2016) 12 (1065-1074) DOI: 10.1038/nchembio.2203);Structural and conformational determinants of macrocycle cell permeability

Nature Chemical Biology

Volumn 12, Issue 12, 2016, Pages 1065-1074

  Over, Björn ^a   Matsson, Pär ^b   Tyrchan, Christian ^a   Artursson, Per ^b   Doak, Bradley C ^b   Foley, Michael A ^c,e   Hilgendorf, Constanze ^a   Johnston, Stephen E ^c   Lee, Maurice D ^c,e,f   Lewis, Richard J ^a   McCarren, Patrick ^c   Muncipinto, Giovanni ^c,e,f   Norinder, Ulf ^d   Perry, Matthew W D ^a   Duvall, Jeremy R ^c,e,f   Kihlberg, Jan ^b  

^a ASTRAZENECA R AND D   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d Swedish Toxicology Sciences Research Center   (Sweden)

^e Tri Institutional Therapeutics Discovery Institute Inc   (United States)

^f Ensemble Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MACROCYCLIC COMPOUND;

ARTICLE; CELL MEMBRANE PERMEABILITY; CHEMICAL STRUCTURE; CLINICAL TRIAL; DRUG CONFORMATION; HUMAN; LIPOPHILICITY; MOLECULAR INTERACTION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SOLUBILITY; STEREOCHEMISTRY; STEREOISOMERISM; CACO-2 CELL LINE; CHEMISTRY; PERMEABILITY; STRUCTURE ACTIVITY RELATION;

CACO-2 CELLS; HUMANS; MACROCYCLIC COMPOUNDS; MOLECULAR STRUCTURE; PERMEABILITY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84991737663     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio0817-922a     Document Type: Erratum

References (52)

1. Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3-26 (2001).
2. Doak, B. C., Zheng, J., Dobritzsch, D. & Kihlberg, J. How beyond rule of 5 drugs and clinical candidates bind to their targets. J. Med. Chem. 59, 2312-2327 (2016).
3. Doak, B. C., Over, B., Giordanetto, F. & Kihlberg, J. Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates. Chem. Biol. 21, 1115-1142 (2014).
4. Driggers, E. M., Hale, S. P., Lee, J. & Terrett, N. K. The exploration of macrocycles for drug discovery-an underexploited structural class. Nat. Rev. Drug Discov. 7, 608-624 (2008).
5. Surade, S. & Blundell, T. L. Structural biology and drug discovery of difficult targets: the limits of ligandability. Chem. Biol. 19, 42-50 (2012).
6. Mallinson, J. & Collins, I. Macrocycles in new drug discovery. Future Med. Chem. 4, 1409-1438 (2012).
7. Giordanetto, F. & Kihlberg, J. Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties? J. Med. Chem. 57, 278-295 (2014).
8. Villar, E. A. et al. How proteins bind macrocycles. Nat. Chem. Biol. 10, 723-731 (2014).
9. Bockus, A. T. et al. Probing the physicochemical boundaries of cell permeability and oral bioavailability in lipophilic macrocycles inspired by natural products. J. Med. Chem. 58, 4581-4589 (2015).
10. Hewitt, W. M. et al. Cell-permeable cyclic peptides from synthetic libraries inspired by natural products. J. Am. Chem. Soc. 137, 715-721 (2015).
11. Nielsen, D. S. et al. Improving on nature: making a cyclic heptapeptide orally bioavailable. Angew. Chem. Int. Ed. Engl. 53, 12059-12063 (2014).
12. Wang, C. K. et al. Rational design and synthesis of an orally bioavailable peptide guided by NMR amide temperature coefficients. Proc. Natl. Acad. Sci. USA 111, 17504-17509 (2014).
13. Rosenquist, Å. et al. Discovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitor. J. Med. Chem. 57, 1673-1693 (2014).
14. Rezai, T. et al. Conformational flexibility, internal hydrogen bonding, and passive membrane permeability: successful in silico prediction of the relative permeabilities of cyclic peptides. J. Am. Chem. Soc. 128, 14073-14080 (2006).
15. Thansandote, P. et al. Improving the passive permeability of macrocyclic peptides: balancing permeability with other physicochemical properties. Bioorg. Med. Chem. 23, 322-327 (2015).
16. Wang, C. K. et al. Exploring experimental and computational markers of cyclic peptides: charting islands of permeability. Eur. J. Med. Chem. 97, 202-213 (2015).
17. Schreiber, S. L. Organic chemistry: molecular diversity by design. Nature 457, 153-154 (2009).
18. Lovering, F. Escape from flatland 2: complexity and promiscuity. Med. Chem. Commun. 4, 515-519 (2013).
19. Fitzgerald, M. E. et al. Build/couple/pair strategy for the synthesis of stereochemically diverse macrolactams via head-to-tail cyclization. ACS Comb. Sci. 14, 89-96 (2012).
20. Marcaurelle, L. A. et al. An aldol-based build/couple/pair strategy for the synthesis of medium-and large-sized rings: discovery of macrocyclic histone deacetylase inhibitors. J. Am. Chem. Soc. 132, 16962-16976 (2010).
21. Comer, E. et al. Fragment-based domain shuffling approach for the synthesis of pyran-based macrocycles. Proc. Natl. Acad. Sci. USA 108, 6751-6756 (2011).
22. Waring, M. J. Lipophilicity in drug discovery. Expert Opin. Drug Discov. 5, 235-248 (2010).
23. Artursson, P. & Karlsson, J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun. 175, 880-885 (1991).
24. Artursson, P., Palm, K. & Luthman, K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Deliv. Rev. 22, 67-84 (1996).
25. Hubatsch, I., Ragnarsson, E. G. & Artursson, P. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat. Protoc. 2, 2111-2119 (2007).
26. Giacomini, K. M. et al. Membrane transporters in drug development. Nat. Rev. Drug Discov. 9, 215-236 (2010).
27. Matsson, P., Pedersen, J. M., Norinder, U., Bergström, C. A. & Artursson, P. Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm. Res. 26, 1816-1831 (2009).
28. Heinis, C. Drug discovery: tools and rules for macrocycles. Nat. Chem. Biol. 10, 696-698 (2014).
29. Matsson, P. et al. Exploring the role of different drug transport routes in permeability screening. J. Med. Chem. 48, 604-613 (2005).
30. Raub, T. J. P-glycoprotein recognition of substrates and circumvention through rational drug design. Mol. Pharm. 3, 3-25 (2006).
31. Zamek-Gliszczynski, M. J. et al. The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice. Mol. Pharmacol. 70, 2127-2133 (2006).
32. Ferreira, R. J., Ferreira, M. J. U. & dos Santos, D. J. V. A. Molecular docking characterizes substrate-binding sites and efflux modulation mechanisms within P-glycoprotein. J. Chem. Inf. Model. 53, 1747-1760 (2013).
33. Desai, P. V., Raub, T. J. & Blanco, M. J. How hydrogen bonds impact P-glycoprotein transport and permeability. Bioorg. Med. Chem. Lett. 22, 6540-6548 (2012).
34. Hitchcock, S. A. Structural modifications that alter the P-glycoprotein efflux properties of compounds. J. Med. Chem. 55, 4877-4895 (2012).
35. Kuhn, B., Mohr, P. & Stahl, M. Intramolecular hydrogen bonding in medicinal chemistry. J. Med. Chem. 53, 2601-2611 (2010).
36. Guimaraães, C. R. W., Mathiowetz, A. M., Shalaeva, M., Goetz, G. & Liras, S. Use of 3D properties to characterize beyond rule-of-5 property space for passive permeation. J. Chem. Inf. Model. 52, 882-890 (2012).
37. Alex, A., Millan, D. S., Perez, M., Wakenhut, F. & Whitlock, G. A. Intramolecular hydrogen bonding to improve membrane permeability and absorption in beyond rule of five chemical space. Med. Chem. Commun. 2, 669-674 (2011).
38. Bockus, A. T. et al. Going out on a limb: delineating the effects of ?-branching, N-methylation, and side chain size on the passive permeability, solubility, and flexibility of Sanguinamide A analogues. J. Med. Chem. 58, 7409-7418 (2015).
39. Varma, M. V. S. et al. Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. J. Med. Chem. 53, 1098-1108 (2010).
40. Mathiowetz, A. M., Leung, S. S. & Jacobson, M. P. in Macrocycles in Drug Discovery Vol. 40 (ed. Levin, J.) 367-397 (Royal Soc. Chem. Press, Cambridge, 2014).
41. Bickerton, G. R., Paolini, G. V., Besnard, J., Muresan, S. & Hopkins, A. L. Quantifying the chemical beauty of drugs. Nat. Chem. 4, 90-98 (2012).
42. Sauer, W. H. B. & Schwarz, M. K. Molecular shape diversity of combinatorial libraries: a prerequisite for broad bioactivity. J. Chem. Inf. Comput. Sci. 43, 987-1003 (2003).
43. Alelyunas, Y. W., Liu, R., Pelosi-Kilby, L. & Shen, C. Application of a Dried-DMSO rapid throughput 24-h equilibrium solubility in advancing discovery candidates. Eur. J. Pharm. Sci. 37, 172-182 (2009).
44. Kalvass, J. C. & Pollack, G. M. Kinetic considerations for the quantitative assessment of efflux activity and inhibition: implications for understanding and predicting the effects of efflux inhibition. Pharm. Res. 24, 265-276 (2007).
45. von Kienlin, M., Moonen, C. T. W., van der Toorn, A. & van Zijl, P. C. M. Rapid recording of solvent-suppressed 2D COSY spectra with inherent quadrature detection using pulsed field gradients. J. Magn. Reson. 93, 423-429 (1991).
46. Willker, W., Leibfritz, D., Kerssebaum, R. & Bermel, W. Gradient selection in inverse heteronuclear correlation spectroscopy. Magn. Reson. Chem. 31, 287-292 (1993).
47. Marion, D. Rotating frame nuclear overhauser effect: a practical tool for the 1H NMR study of peptides in solution. FEBS Lett. 192, 99-103 (1985).
48. Abraham, M. H. et al. An NMR method for the quantitative assessment of intramolecular hydrogen bonding; application to physicochemical, environmental, and biochemical properties. J. Org. Chem. 79, 11075-11083 (2014).
49. Freyhult, E. et al. Unbiased descriptor and parameter selection confirms the potential of proteochemometric modelling. BMC Bioinformatics 6, 50 (2005).
50. Mateus, A., Matsson, P. & Artursson, P. Rapid measurement of intracellular unbound drug concentrations. Mol. Pharm. 10, 2467-2478 (2013).
51. Chang, C. C. & Lin, C. J. LIBSVM: a library for support vector machines. ACM Trans. Intell. Syst. Technol. 2, 27:1-27:27 (2011).
52. Breiman, L. Random forests. Mach. Learn. 45, 5-32 (2001).